Strategies for In Vivo Delivery of siRNAs Recent Progress

被引:97
作者
Higuchi, Yuriko [1 ]
Kawakami, Shigeru [2 ]
Hashida, Mitsuru [2 ,3 ]
机构
[1] Kyoto Univ, Grad Sch Pharmaceut Sci, Inst Innovat NanoBio Drug Discovery & Dev, Kyoto, Japan
[2] Kyoto Univ, Grad Sch Pharmaceut Res, Dept Drug Delivery Res, Kyoto, Japan
[3] Kyoto Univ, Inst Integrated Cell Mat Sci iCeMS, Kyoto, Japan
关键词
SMALL-INTERFERING RNA; PERFUSED RAT-KIDNEY; B DECOY COMPLEXES; CHEMICAL-MODIFICATION; MAMMALIAN-CELLS; PLASMID DNA; GENE-EXPRESSION; INTRACELLULAR DELIVERY; TARGETED DELIVERY; CARBON NANOTUBES;
D O I
10.2165/11534450-000000000-00000
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RNA interference (RNAi) is a post-transcriptional gene-silencing mechanism that involves the degradation of messenger RNA in a highly sequence-specific manner. Double-stranded small interfering RNA (siRNA), consisting of 21-25 nucleotides, can induce RNAi and inhibit the expression of target proteins. Therefore, siRNA is considered a promising therapeutic for treatment of a variety of diseases, including genetic and viral diseases, and cancer. Clinical trials of siRNA are ongoing or have been planned, although some issues need to be addressed. For example, cellular uptake of naked siRNA is extremely low due to its polyanionic nature. Furthermore, siRNA is easily degraded by enzymes in blood, tissues, and cells. Several types of chemically modified siRNA have been produced and investigated to improve stability; these have involved modification of the siRNA backbone, the sugar moiety, and the nucleotide bases of antisense and/or sense strands. Because the accumulation at the target site after administration is extremely low, even if stability is improved, an effective delivery system is required to induce RNAi at the site of action. Delivery strategies can be categorized into physical methods, conjugation methods, and drug delivery system carrier-mediated methods. Physical techniques can enhance siRNA uptake at a specific tissue site using electroporation, pressure, mechanical massage, etc. Terminal modification of siRNAs can enhance their resistance to degradation by exonucleases in serum and tissue. Moreover, modification with a suitable ligand can achieve targeted delivery. Several types of carrier for drug delivery have been developed for siRNA in addition to traditional cationic liposome and cationic polymer systems. Ultrasound and microbubbles or liposomal bubbles have also been used in combination with a carrier for siRNA delivery. New materials with unique characteristics such as carbon nanotubes, gold nanoparticles, and gold nanorods have attracted attention as innovative carriers for siRNA.
引用
收藏
页码:195 / 205
页数:11
相关论文
共 115 条
[1]   Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity [J].
Akhtar, Saghir ;
Benter, Ibrahim .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (2-3) :164-182
[2]   Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis [J].
Akinc, A ;
Thomas, M ;
Klibanov, AM ;
Langer, R .
JOURNAL OF GENE MEDICINE, 2005, 7 (05) :657-663
[3]   A combinatorial library of lipid-like materials for delivery of RNAi therapeutics [J].
Akinc, Akin ;
Zumbuehl, Andreas ;
Goldberg, Michael ;
Leshchiner, Elizaveta S. ;
Busini, Valentina ;
Hossain, Naushad ;
Bacallado, Sergio A. ;
Nguyen, David N. ;
Fuller, Jason ;
Alvarez, Rene ;
Borodovsky, Anna ;
Borland, Todd ;
Constien, Rainer ;
de Fougerolles, Antonin ;
Dorkin, J. Robert ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
John, Matthias ;
Koteliansky, Victor ;
Manoharan, Muthiah ;
Nechev, Lubomir ;
Qin, June ;
Racie, Timothy ;
Raitcheva, Denitza ;
Rajeev, Kallanthottathil G. ;
Sah, Dinah W. Y. ;
Soutschek, Juergen ;
Toudjarska, Ivanka ;
Vornlocher, Hans-Peter ;
Zimmermann, Tracy S. ;
Langer, Robert ;
Anderson, Daniel G. .
NATURE BIOTECHNOLOGY, 2008, 26 (05) :561-569
[4]   Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver [J].
Akinc, Akin ;
Goldberg, Michael ;
Qin, June ;
Dorkin, J. Robert ;
Gamba-Vitalo, Christina ;
Maier, Martin ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
Rajeev, Kallanthottathil G. ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
Roehl, Ingo ;
Leshchiner, Elizaveta S. ;
Langer, Robert ;
Anderson, Daniel G. .
MOLECULAR THERAPY, 2009, 17 (05) :872-879
[5]   Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA [J].
Allerson, CR ;
Sioufi, N ;
Jarres, R ;
Prakash, TP ;
Naik, N ;
Berdeja, A ;
Wanders, L ;
Griffey, RH ;
Swayze, EE ;
Bhat, B .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :901-904
[6]   Tolerance for mutations and chemical modifications in a siRNA [J].
Amarzguioui, M ;
Holen, T ;
Babaie, E ;
Prydz, H .
NUCLEIC ACIDS RESEARCH, 2003, 31 (02) :589-595
[7]   Synthesis and Characterization of a Carbon Nanotube-Dendron Series for Efficient siRNA Delivery [J].
Antonia Herrero, M. ;
Toma, Francesca M. ;
Al-Jamal, Khuloud T. ;
Kostarelos, Kostas ;
Bianco, Alberto ;
Da Ros, Tatiana ;
Bano, Fouzia ;
Casalis, Loredana ;
Scoles, Giacinto ;
Prato, Maurizio .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (28) :9843-9848
[8]   Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation [J].
Aouadi, Myriam ;
Tesz, Gregory J. ;
Nicoloro, Sarah M. ;
Wang, Mengxi ;
Chouinard, My ;
Soto, Ernesto ;
Ostroff, Gary R. ;
Czech, Michael P. .
NATURE, 2009, 458 (7242) :1180-U116
[9]   Chemical Modification of siRNAs for In Vivo Use [J].
Behlke, Mark A. .
OLIGONUCLEOTIDES, 2008, 18 (04) :305-319
[10]   Nanotechnology approach for drug addiction therapy: Gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons [J].
Bonoiu, Adela C. ;
Mahajan, Supriya D. ;
Ding, Hong ;
Roy, Indrajit ;
Yong, Ken-Tye ;
Kumar, Rajiv ;
Hu, Rui ;
Bergey, Earl J. ;
Schwartz, Stanley A. ;
Prasad, Paras N. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (14) :5546-5550